Clinuvel Pharmaceuticals Limited Profit Margin

Clinuvel Pharmaceuticals Limited (CLVLY) currently reports a profit margin of 38.11% as of December 2025. That compares with 37.28% in the prior-year period — up 2.2% year over year. That is above the Healthcare sector average of 9.71%. Use the charts on this page to explore Clinuvel Pharmaceuticals Limited's profit margin history and peer comparisons.

Clinuvel Pharmaceuticals Limited's profit margin increased from 37.28% to 38.11% — a 2.2% year-over-year increase (period ending December 2025). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Clinuvel Pharmaceuticals Limited's profit margin of 38.11% is higher than the Healthcare sector average of 9.71%. That is roughly 292.6% above the sector mean. A reading higher peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

There is no universal 'good' profit margin, but Clinuvel Pharmaceuticals Limited's current 38.11% should be judged against Healthcare norms (sector average: 9.71%) and against CLVLY's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.

Start with the current profit margin of 38.11%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 9.71%. From there, open related valuation or income-statement pages for Clinuvel Pharmaceuticals Limited, and consider following CLVLY for alerts when major investors trade the stock.